MOLECULAR MECHANISMS OF DRUG-RESISTANCE IN TUMORS

被引:75
作者
HARRISON, DJ
机构
[1] CRC Laboratories, Department of Pathology, University Medical School, Edinburgh, EH8 9AG, Teviot Place
关键词
DRUG RESISTANCE; MDR1; CYTOCHROME P450; GLUTATHIONE; TOPOISOMERASE; P53; APOPTOSIS; CANCER CHEMOTHERAPY;
D O I
10.1002/path.1711750103
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Despite advances in the design and use of chemotherapeutic drugs, the majority of human cancers are resistant to therapy at presentation or become resistant after an initial partial response. this suggests that resistance may be inherent in a tumour cell or may evolve under the selection pressure of drug administration. A number of possible molecular explanations for drug resistance exist. There may be exclusion of drug from the cell, failure to activate the prodrug to its active form, increased detoxification, alteration in the drug target, enahanced repair capability of the cell after injury, or failure to engage an appropriate response, leading to apoptosis in the damaged cell. Many of these factors may co-exist in vivo in human tumours; some are a feature of cell lineage whilst others appear de novo during disease progression. Modulation of these mechanisms has been of some value in laboratory studies but widespread clinical application and benefit remain some way off.
引用
收藏
页码:7 / 12
页数:6
相关论文
共 27 条
  • [11] Powis G, Prough RA, Metabolism and Action of Anticancer Drugs, (1987)
  • [12] Nebert DW, Nelson DR, Coon MJ, Et al., The P450 superfamily: update on new sequences, gene mapping and recommended nomenclature, DNA Cell Biol, 10, pp. 1-14, (1991)
  • [13] Hayes JD, Wolf CR, Molecular mechanisms of drug resistance, Biochem J, 272, pp. 281-295, (1990)
  • [14] Smith G, Harrison DJ, East N, Rae F, Wolf CR, Regulation of cytochrome P450 gene expression in human colon and breast tumour xenografts, Br J Cancer, 68, pp. 57-63, (1993)
  • [15] Schecter RL, Alaoui-Jalami MA, Batist G, Glutathione S‐transferase in chemotherapy resistance and carcinogenesis, Biochem Cell Biol, 70, pp. 349-353, (1992)
  • [16] Harrison DJ, Glutathione S‐transferase localisation in human tumours, Human Drug Metabolism: from Molecular Biology to Man, pp. 125-132, (1993)
  • [17] Gekeler V, Frese G, Noller A, Et al., Mdr1/P‐glycoprotein, topoisomerase, and glutathione‐S‐transferase π gene expression in primary and relapsed state adult and childhood leukaemia, Br J Cancer, 66, pp. 507-517, (1992)
  • [18] Black SM, Beggs JD, Hayes JD, Et al., Expression of human glutathione S‐transferases in Saccharomyces cerevisiae confers resistance to anti‐cancer drug adriamycin and chlorambucil, Biochem J, 268, pp. 309-315, (1990)
  • [19] Sato Y, Fuji Y, Kaneko T, Antiproliferative effects of glutathione S‐transferase inhibitors on the K562 cell line, Biochem Pharmacol, 39, pp. 1263-1266, (1990)
  • [20] McCaughan FM, Brown AL, Harrison DJ, The effect of inhibition of glutathione S‐transferase P on the growth of the Jurkat human T cell line, J Pathol, 172, pp. 357-362, (1994)